Summary
Rusnano Corporation (Rusnano) is an open joint stock company which develops Russian nanotechnology industry through co-investing in nanotechnology projects. It offers its service for a business entity and for non-commercial organization. The company's services include business structuring, co-financing, developing, control and investment of business entities. Its non-commercial organization services include management of nanotechnology centers, engineering companies, certification support, metrology, education, improving legislation, popularizing nanotechnology and infrastructure, among others. Rusnano's portfolio companies include Aquantia Corporation, Selecta Biosciences, Inc., Selecta RUS, Joule Unlimited, and OJSC Pharmsynthez, among others. It operates through its subsidiaries such as Rusnano US, Inc., Rusnano Israel Ltd., Rusnano Capital and Rusnanotech Forum Fund. The company is headquartered in Moscow, Russia.
Rusnano Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Rusnano Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Rusnano Corporation, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Rusnano Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Rusnano Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Rusnano Corporation, Medical Devices Deals, 2010 to YTD 2016 11
Rusnano Corporation, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
Rusnano Corporation, Pharmaceuticals & Healthcare, Deal Details 17
Venture Financing 17
Solix Biosystems Vostok Raises Funds through Venture Financing 17
Tragara Pharma Raises USD13 Million in Series C Financing 18
Syndax Pharma Raises USD80 Million in Series C Financing 20
Selecta Biosciences Raises More than USD20 Million in Venture Financing 22
Clearside Biomedical Raises USD16 Million in Series B Venture Financing 24
Aldea Pharma Raises USD24 Million in Series B Venture Financing 26
Bioptix Raises USD1.4 Million in Venture Financing 28
Epic Sciences Raises USD30 Million in Series C Venture Financing 29
NovaDigm Therapeutics Raises US$14 Million In Series B Financing 31
Tragara Pharma Raises US$12 Million In Extended Series B Financing 33
Syndax Pharma Raises US$27 Million In Series B Venture Financing 35
Lithera Raises US$35.6 Million In Series C Financing 37
Marinus Pharma Raises US$21 Million In Series C Financing 39
Regado Biosciences Raises US$51 Million In Series E Financing 41
CoDa Therapeutics Raises Additional US$20 Million In Series B Financing 43
Selecta Biosciences Secures US$47 Million In Series D Financing Round 45
Bind Biosciences Secures US$35 Million In Series D Financing Round 47
Bioptix Diagnostics Raises US$9 Million In Series B Financing 50
Partnerships 51
Domain Associates Forms Joint Venture With Rusnano 51
Rusnano, Human Stem Cells Institute, Pharmsynthez, Cryonix, And FDS Pharma Form SynBio 52
RUSNANO Enters Into Joint Venture Agreement With NEARMEDIC PLUS 54
Cleveland BioLabs Forms Joint Venture With RUSNANO 55
Celtic Pharma Forms Joint Venture With Russian Corporation Of Nanotechnologies 57
Rusnano Enters into Joint Venture Agreement with Epidbiomed 59
Chemrar Enters Into Joint Venture Agreement With Rusnano 60
MP Biomedicals Enters Into Co-Development Agreement With RUSNANO 61
MP Biomedicals Enters Into An Agreement With RUSNANO 62
Equity Offering 63
Farmsintez to Raise USD47.9 Million in Private Placement of Additional Shares 63
Farmsintez to Raise USD66.6 Million in Private Placement of Shares 64
Acquisition 65
Rusnano Acquires Minority Stake In Pharmsynthez For US$26.1 Million 65
IPG Photonics Acquires Remaining 22.5% Stake In NTO IRE-Polus From Rusnano For US$55.4 Million 66
Rusnano Corporation - Key Competitors 67
Key Employees 68
Locations And Subsidiaries 69
Head Office 69
Other Locations & Subsidiaries 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70
List of Tables
Rusnano Corporation, Pharmaceuticals & Healthcare, Key Facts 1
Rusnano Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Rusnano Corporation, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Rusnano Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Rusnano Corporation, Deals By Therapy Area, 2010 to YTD 2016 9
Rusnano Corporation, Medical Devices Deals, 2010 to YTD 2016 11
Rusnano Corporation, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
Solix Biosystems Vostok Raises Funds through Venture Financing 17
Tragara Pharma Raises USD13 Million in Series C Financing 18
Syndax Pharma Raises USD80 Million in Series C Financing 20
Selecta Biosciences Raises More than USD20 Million in Venture Financing 22
Clearside Biomedical Raises USD16 Million in Series B Venture Financing 24
Aldea Pharma Raises USD24 Million in Series B Venture Financing 26
Bioptix Raises USD1.4 Million in Venture Financing 28
Epic Sciences Raises USD30 Million in Series C Venture Financing 29
NovaDigm Therapeutics Raises US$14 Million In Series B Financing 31
Tragara Pharma Raises US$12 Million In Extended Series B Financing 33
Syndax Pharma Raises US$27 Million In Series B Venture Financing 35
Lithera Raises US$35.6 Million In Series C Financing 37
Marinus Pharma Raises US$21 Million In Series C Financing 39
Regado Biosciences Raises US$51 Million In Series E Financing 41
CoDa Therapeutics Raises Additional US$20 Million In Series B Financing 43
Selecta Biosciences Secures US$47 Million In Series D Financing Round 45
Bind Biosciences Secures US$35 Million In Series D Financing Round 47
Bioptix Diagnostics Raises US$9 Million In Series B Financing 50
Domain Associates Forms Joint Venture With Rusnano 51
Rusnano, Human Stem Cells Institute, Pharmsynthez, Cryonix, And FDS Pharma Form SynBio 52
RUSNANO Enters Into Joint Venture Agreement With NEARMEDIC PLUS 54
Cleveland BioLabs Forms Joint Venture With RUSNANO 55
Celtic Pharma Forms Joint Venture With Russian Corporation Of Nanotechnologies 57
Rusnano Enters into Joint Venture Agreement with Epidbiomed 59
Chemrar Enters Into Joint Venture Agreement With Rusnano 60
MP Biomedicals Enters Into Co-Development Agreement With RUSNANO 61
MP Biomedicals Enters Into An Agreement With RUSNANO 62
Farmsintez to Raise USD47.9 Million in Private Placement of Additional Shares 63
Farmsintez to Raise USD66.6 Million in Private Placement of Shares 64
Rusnano Acquires Minority Stake In Pharmsynthez For US$26.1 Million 65
IPG Photonics Acquires Remaining 22.5% Stake In NTO IRE-Polus From Rusnano For US$55.4 Million 66
Rusnano Corporation, Key Competitors 67
Rusnano Corporation, Key Employees 68
Rusnano Corporation, Subsidiaries 69
List of Figures
Rusnano Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Rusnano Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Rusnano Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Rusnano Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Rusnano Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Rusnano Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
Rusnano Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Rusnano Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Rusnano Corporation, Medical Devices Deals, 2010 to YTD 2016 11
